Cholecystokinin (27-32)-amide | CAS#86367-90-0 | CCK receptor antagonist

MedKoo Cat#: 596828 | Name: Cholecystokinin (27-32)-amide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cholecystokinin (27-32)-amide is a CCK C-terminal heptapeptide minus COOH-terminal Phe residue; CCK receptor antagonist.

Chemical Structure

Cholecystokinin (27-32)-amide

CAS#86367-90-0

Theoretical Analysis

MedKoo Cat#: 596828

Name: Cholecystokinin (27-32)-amide

CAS#: 86367-90-0

Chemical Formula: C36H48N8O12S3

Exact Mass: 880.2554

Molecular Weight: 881.00

Elemental Analysis: C, 49.08; H, 5.49; N, 12.72; O, 21.79; S, 10.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Cholecystokinin (27-32)-amide; Cholecystokinin (27-32)-NH2;

IUPAC/Chemical Name

(5S,11S,14S,17S)-11-((1H-indol-3-yl)methyl)-5-((S)-2-amino-3-(4-(sulfooxy)phenyl)propanamido)-17-carbamoyl-14-(2-(methylthio)ethyl)-6,9,12,15-tetraoxo-2-thia-7,10,13,16-tetraazanonadecan-19-oic acid

InChi Key

WUUXPYBWGKLWBA-CISYKLKFSA-N

InChi Code

InChI=1S/C36H48N8O12S3/c1-57-13-11-26(42-33(49)24(37)15-20-7-9-22(10-8-20)56-59(53,54)55)34(50)40-19-30(45)41-29(16-21-18-39-25-6-4-3-5-23(21)25)36(52)43-27(12-14-58-2)35(51)44-28(32(38)48)17-31(46)47/h3-10,18,24,26-29,39H,11-17,19,37H2,1-2H3,(H2,38,48)(H,40,50)(H,41,45)(H,42,49)(H,43,52)(H,44,51)(H,46,47)(H,53,54,55)/t24-,26-,27-,28-,29-/m0/s1

SMILES Code

O=C(O)C[C@@H](C(N)=O)NC([C@H](CCSC)NC([C@H](CC1=CNC2=C1C=CC=C2)NC(CNC([C@H](CCSC)NC([C@H](CC3=CC=C(OS(=O)(O)=O)C=C3)N)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 881.00 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tarasova NI, Stauber RH, Choi JK, Hudson EA, Czerwinski G, Miller JL, Pavlakis GN, Michejda CJ, Wank SA. Visualization of G protein-coupled receptor trafficking with the aid of the green fluorescent protein. Endocytosis and recycling of cholecystokinin receptor type A. J Biol Chem. 1997 Jun 6;272(23):14817-24. PubMed PMID: 9169450. 2: Staley J, Jensen RT, Moody TW. CCK antagonists interact with CCK-B receptors on human small cell lung cancer cells. Peptides. 1990 Sep-Oct;11(5):1033-6. PubMed PMID: 2178246. 3: Menozzi D, Gardner JD, Jensen RT, Maton PN. Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am J Physiol. 1989 Jul;257(1 Pt 1):G73-9. PubMed PMID: 2473654. 4: Barone FC, Bondinell WE, Labosh TJ, White RF, Ormsbee HS 3rd. Cholecystokinin stimulates neuronal receptors to produce contraction of the canine colon. Life Sci. 1989;44(8):533-42. PubMed PMID: 2927258. 5: Vinayek R, Jensen RT, Gardner JD. Role of sulfate ester in influencing biologic activity of cholecystokinin-related peptides. Am J Physiol. 1987 Feb;252(2 Pt 1):G178-81. PubMed PMID: 2435164. 6: Yoder DG, Moody TW. High affinity binding of cholecystokinin to small cell lung cancer cells. Peptides. 1987 Jan-Feb;8(1):103-7. PubMed PMID: 3033616. 7: Otsuki M, Okabayashi Y, Ohki A, Oka T, Fujii M, Nakamura T, Sugiura N, Yanaihara N, Baba S. Action of cholecystokinin analogues on exocrine and endocrine rat pancreas. Am J Physiol. 1986 Apr;250(4 Pt 1):G405-11. PubMed PMID: 2421584. 8: Vigna SR, Szecòwka J, Williams JA. Do antagonists of pancreatic cholecystokinin receptors interact with central nervous system cholecystokinin receptors? Brain Res. 1985 Sep 23;343(2):394-7. PubMed PMID: 2996701. 9: Briet C, Aumelas A, Martinez J. Synthesis of Z-CCK-27-32-NH2, Z-Tyr(SO-3)-Met-Gly-Trp-Met-Asp-NH2, a cholecystokinin receptor antagonist and an inhibitor of gastrin-induced acid secretion. Int J Pept Protein Res. 1985 Sep;26(3):294-8. PubMed PMID: 2997059. 10: Martinez J, Bali JP. A new class of potent gastrin antagonists. Regul Pept. 1984 Nov;9(4):259-62. PubMed PMID: 6097950. 11: Howard JM, Knight M, Jensen RT, Gardner JD. Discovery of a cholecystokinin analogue with partial agonist activity. Am J Physiol. 1984 Sep;247(3 Pt 1):G261-4. PubMed PMID: 6206732. 12: Spanarkel M, Martinez J, Briet C, Jensen RT, Gardner JD. Cholecystokinin-27-32-amide. A member of a new class of cholecystokinin receptor antagonists. J Biol Chem. 1983 Jun 10;258(11):6746-9. PubMed PMID: 6304053.